Lakefront Biotherapeutics | GLPG - Equity Capital And Reserves


Lakefront Biotherapeutics reported EUR3.25B in Equity Capital and Reserves for its fiscal quarter ending in March of 2026.





Equity Capital And Reserves Change Date
argenx SE USD 7.32B 1.23B Dec/2025
AstraZeneca USD 47.33B 1.33B Mar/2026
Biogen USD 18.65B 394.9M Mar/2026
Genmab DKK 5.85B 96M Dec/2025
Gilead Sciences USD 23.52B 897M Mar/2026
GlaxoSmithKline GBP 17.42B 1.05B Mar/2026
GRIFOLS EUR 5.46B 171M Mar/2026
Hikma Pharmaceutical USD 2.59B 42M Dec/2025
Incyte USD 5.62B 455.37M Mar/2026
Merck EUR 29.74B 1.15B Mar/2026
Neurocrine Biosciences USD 3.41B 154.3M Mar/2026
Novartis USD 38.93B 7.2B Mar/2026
Roche Holding CHF 33.8B 758M Dec/2025
Sanofi EUR 72.81B 1.1B Mar/2026
UCB EUR 10.87B 1.18B Dec/2025
Vertex Pharmaceuticals USD 19.36B 696.1M Mar/2026